Leukemia strikes Seattle schools chief Stanford

April 1998
Jet;04/27/98, Vol. 93 Issue 22, p55
Reports that Seattle schools superintendent, John Stanford, was diagnosed with acute myelogenous leukemia. Comments from Stanford; Background information on Stanford.


Related Articles

  • A soldier's story. Keller, Bess // Teacher Magazine;Oct98, Vol. 10 Issue 2, p13 

    Focuses on how the people of Seattle, Washington supported school superintendent John Stanford, who is suffering from leukemia. Filmmakers interested in Stanford's story; Information on Stanford's tenure as superintendent; Stem-cell transplant undergone by Stanford.

  • Seattle rallies behind Stanford as he battles illness. Keller, Bess // Education Week;09/09/98, Vol. 18 Issue 1, p3 

    Comments on the fact that the entire state of Seattle has expressed its complete support of John Stanford, Superintendent of Seattle, who was diagnosed with leukemia. Reference to numerous monetary contributions issued to a foundation established by Standford; Factors contributing to Stanford's...

  • Uninsured AML patients less likely to receive chemotherapy.  // PharmacoEconomics & Outcomes News;4/16/2011, Issue 626, p10 

    The article discusses a report published in "Cancer" magazine which confirms that treatment for acute myeloid leukaemia (AML) has been limited to patients who have health insurance, while uninsured patients have a higher chance of being untreated or dying from AML.

  • Therapy of older persons with acute myeloid leukemia. Gale, R P; Hochhaus, A // Leukemia (08876924);Apr2015, Vol. 29 Issue 4, p759 

    The article discusses the therapy of older persons with acute myeloid leukemia.

  • Pediatric Acute Myeloid Leukemia as Classified Using 2008 WHO Criteria. Davis, Kara L.; Marina, Neyssa; Arber, Daniel A.; Ma, Lisa; Cherry, Athena; Dahl, Gary V.; Heerema-McKenney, Amy // American Journal of Clinical Pathology;Jun2013, Vol. 139 Issue 6, p818 

    The classification of acute myeloid leukemia (AML) has evolved to the most recent World Health Organization (WHO) schema, which integrates genetic, morphologic, and prognostic data into a single system. However, this system was devised using adult data and how this system applies to a pediatric...

  • Impact of Chemotherapy Delay on Overall Survival for AML with IDH1/2 Mutations: A Study in Adult Chinese Patients. Wang, Jing-Han; Guo, Qi; Ma, Zhi-Xin; Ma, Qiu-Ling; Yu, Meng-Xia; Yin, Xiu-Feng; Lu, Sha-Sha; Xie, Hong-Qiong; Jiang, Yue-Hong; Shen, Dan; Ma, Li-Ya; Shi, Hui; Yu, Wen-Juan; Lou, Ye-Jiang; Li, Ying; Yang, Min; Xu, Gai-Xiang; Mao, Li-Ping; Li, Jian-Hu; Wang, Huan-Ping // PLoS ONE;10/14/2015, Vol. 10 Issue 10, p1 

    The effect of time from diagnosis to treatment (TDT) on overall survival of patients with acute myeloid leukemia (AML) remains obscure. Furthermore, whether chemotherapy delay impacts overall survival (OS) of patients with a special molecular subtype has not been investigated. Here, we enrolled...

  • Acute Myeloid Leukemia Diagnosis in the 21st Century. Betz, Bryan L.; Hess, Jay L. // Archives of Pathology & Laboratory Medicine;Oct2010, Vol. 134 Issue 10, p1427 

    Context.--Rapid advances in understanding the molecular biology of acute myeloid leukemia are transforming the approach to diagnosis, prognostication, and treatment of these cases. Objective.--To briefly review the current state of AML classification with a particular emphasis on the role of...

  • Acute Myeloid Leukemia Genetics. Wang, Michael L.; Bailey, Nathanael G. // Archives of Pathology & Laboratory Medicine;Oct2015, Vol. 139 Issue 10, p1215 

    Acute myeloid leukemia is a category of diseases with a common aggressive clinical presentation but with a prognosis and management that is dependent upon the underlying genetic characteristics of the neoplasm. The purpose of this brief review is to update the practicing pathologist on the...

  • Nature: Cancer scientists link 'oncometabolite' to onset of acute myeloid leukemia.  // Biomedical Market Newsletter;7/19/2012, Vol. 21, p1 

    The article discusses a study by a team of international scientists led by Tak Mak at the Princess Margaret Cancer Centre, University Health Network which informs about a link between the product of a mutated metabolic enzyme and the onset of acute myeloid leukemia (AML).


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics